Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Numerator
Net loss	$ (35,843)	$ (41,053)	$ (110,760)	$ (114,852)
Less: Net loss attributable to noncontrolling interest	$ (19,374)	$ (23,143)	$ (61,005)	$ (74,944)
Antidilutive securities
Earnout Rights			17,500,000	17,500,000
Stock options granted under the 2022 Equity Incentive Plan	29,090,638	22,076,832	29,090,638	22,076,832
Restricted Stock Rights [Member]
Antidilutive securities
Unvested Restricted Stock Rights			740,933	1,755,686
Common Class A [Member]
Numerator
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic	$ (16,469)	$ (17,910)	$ (49,755)	$ (39,908)
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted	$ (16,469)	$ (17,910)	$ (49,755)	$ (39,908)
Denominator
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic	134,992,796	126,173,463	131,588,705	87,818,229
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted	134,992,796	126,173,463	131,588,705	87,818,229
Net loss per share attributable to Class A common stock, Basic	$ (0.12)	$ (0.14)	$ (0.38)	$ (0.45)
Net loss per share attributable to Class A common stock, Diluted	$ (0.12)	$ (0.14)	$ (0.38)	$ (0.45)
Antidilutive securities
ProKidney Corp. ordinary shares	135,977,945		135,977,945		128,054,417
Common Class B [Member]
Antidilutive securities
ProKidney Corp. ordinary shares	159,288,931	163,741,676	159,288,931	163,741,676	163,693,707